drugset / Trial / NCT04318639

The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder

NCT04318639

Phase 2/3 Completed 15 enrolled VA Connecticut Healthcare System
NaSingle-groupOpen-labelTreatment

Summary

This is an open label feasibility trial to learn whether the combination of donepezil and cognitive remediation therapy (Donepezil + CRT) may improve neurocognitive functioning and decreasing alcohol use in Veterans with alcohol use disorder who have mild cognitive impairment (AUD-MCI). The study will determine the acceptability and adherence to treatment and preliminary evidence for efficacy. The study will recruit 15 newly recovering Veterans individuals with AUD-MCI for a 13-week, open-label, single-arm pilot study with sobriety and cognitive assessments at baseline and at 13-week follow-up.

Timeline

Start
2018-08-17
Primary completion
2019-12-31
Completion
2019-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 10 mg